Asieris to Showcase Cevira Phase III Results at EUROGIN 2024

A significant development in the medical field is set to be showcased at the 2024 European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference. The event, which is scheduled to take place from March 13 to 16 in Stockholm, will feature an oral presentation on a groundbreaking non-surgical treatment for cervical high-grade squamous intraepithelial lesions (HSIL). The treatment, known as Cevira® (APL-1702), is a product of a collaboration between Photocure ASA and Asieris Pharmaceuticals.

Cevira represents an innovative approach to addressing precancerous cervical lesions without the need for invasive surgery. Developed by Photocure through initial phases of clinical trials, the product is a photodynamic drug-device combination. In 2019, the rights for further development and commercialization were transferred to Asieris Meditech Co., Ltd, a biopharmaceutical firm with a focus on genitourinary tumors and related diseases.

The upcoming presentation at EUROGIN will mark the first public disclosure of the results from a randomized phase III global study (YHGT-CEV-R1/APRICITY). This study is a key milestone in validating the efficacy and safety of APL-1702, potentially positioning it as a pioneering non-surgical solution for HSIL. EUROGIN, recognized for its interdisciplinary approach to HPV-related research, seeks to integrate scientific findings into clinical practices, thereby reducing the impact of HPV-associated cancers.

Photocure ASA, a company renowned for its contributions to bladder cancer treatment, has a proprietary technology that makes cancer cells visibly distinct, facilitating improved patient outcomes. Based in Oslo, Norway, and listed on the Oslo Stock Exchange, Photocure continues to be at the forefront of medical advancements in cancer treatment.

The forthcoming EUROGIN conference promises to be a platform for discussing and celebrating the progress made in the fight against HPV-induced cancers, with Cevira's phase III clinical study results being a highlight of the scientific program. The collaboration between Photocure and Asieris exemplifies the power of joint efforts in the pharmaceutical industry to develop novel treatments that could transform patient care globally.